Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENURONE vs AZMIRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Adjunctive therapy in the treatment of partial seizures with or without secondary generalization,Off-label: refractory epilepsy, complex partial seizures
Treatment of Ductal Carcinoma In Situ (DCIS) following breast surgery and radiation,Breast cancer risk reduction in premenopausal women at high risk,Off-label: Anovulatory infertility, Osteoporosis prevention in postmenopausal women
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Primarily hepatic metabolism via hydrolysis and conjugation; involves CYP450 enzymes (minor contribution). Metabolites are excreted in urine.
Primarily metabolized via hepatic glucuronidation by UGT1A4 and UGT1A8; minor metabolism by CYP3A4; excreted mainly in feces.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Approximately 80-90% bound, primarily to serum albumin. The binding is saturable, which can lead to nonlinear pharmacokinetics at high doses.
98% bound to albumin and alpha-1-acid glycoprotein.
0.5-1.0 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding. Vd may be increased in epilepsy or with co-administration of other anticonvulsants.
0.8 L/kg; indicates moderate tissue distribution.
Oral bioavailability is approximately 90-100% based on absorption studies. Food does not significantly affect absorption.
Oral: 60% (first-pass metabolism reduces to ~60% absolute).
No specific guidelines; use with caution in renal impairment. Monitor for toxicity.
Cr Cl ≥50 m L/min: no adjustment; Cr Cl 30-49 m L/min: 400 mg every 8 hours; Cr Cl 15-29 m L/min: 300 mg every 12 hours; Cr Cl <15 m L/min or hemodialysis: 300 mg every 24 hours.
Child-Pugh Class A: No adjustment; Class B: Reduce dose by 25-50%; Class C: Avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 400 mg every 8 hours; Child-Pugh C: 300 mg every 12 hours.
Children: 10-20 mg/kg/day orally in 2-3 divided doses; maximum 1.5 g/day.
For children ≥2 years: 10 mg/kg/dose IV every 8 hours, maximum 600 mg/dose.
Initiate at low end of dosing range (500 mg/day) and titrate slowly; monitor for neurotoxicity.
No specific dose adjustment based solely on age; dose based on renal function as per renal adjustment guidelines.
Phenacemide may cause fatal hepatotoxicity and aplastic anemia. Patients must be closely monitored for signs of hepatic dysfunction and blood dyscrasias.
Increased risk of thromboembolic events including deep vein thrombosis and pulmonary embolism; increased risk of endometrial cancer, uterine sarcoma, and stroke.
Hepatotoxicity: monitor liver function tests at baseline and periodically; discontinue if signs of hepatic injury. Aplastic anemia: advise patients to report unexplained bleeding, bruising, or signs of infection. Suicidal ideation: monitor for changes in mood or behavior. Withdrawal: do not discontinue abruptly.
Risk of thromboembolic events; endometrial hyperplasia and malignancy; hepatic steatosis and elevated liver enzymes; cataracts; hypertriglyceridemia; use in pregnancy category N (should not be used during pregnancy).
History of liver disease or hepatic dysfunction. History of aplastic anemia or bone marrow depression. Hypersensitivity to phenacemide or other hydantoins. Concurrent use with other hepatotoxic drugs.
History of venous thromboembolism; pregnancy; women with a history of stroke or transient ischemic attack; hypersensitivity to azmiro or its components.
No significant food interactions documented. Avoid alcohol entirely due to additive CNS depression and potential hepatotoxicity.
No significant food interactions. Avoid grapefruit juice as it may increase systemic budesonide exposure. Maintain adequate calcium and vitamin D intake due to potential bone density loss with long-term use.
Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.
No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).
Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects (e.g., sedation, poor feeding) in the infant.
No data on excretion in human milk; unknown M/P ratio. Risk to infant cannot be excluded; consider developmental benefits of breastfeeding versus theoretical risk.
Due to increased clearance in pregnancy, monitor serum concentrations and adjust dose to maintain therapeutic levels; may require dose increases by 20-30%.
No specific dose adjustments studied; pharmacokinetics in pregnancy unknown. Use lowest effective dose and monitor therapeutic response.
Phenurone (phenacemide) is a last-line anticonvulsant due to high risk of hepatotoxicity and bone marrow suppression. Monitor LFTs and CBC monthly. Avoid in patients with liver disease or history of psychosis. Therapeutic drug monitoring: target serum phenacemide level 5-12 mcg/m L. May cause severe personality changes and suicidal ideation.
AZMIRO (budesonide/albuterol) is a fixed-dose combination inhaler for asthma. Due to its LABA component, it should not be used for acute bronchospasm. Titrate to the lowest effective dose. Rinse mouth after inhalation to reduce oral candidiasis and dysphonia. Monitor for increased heart rate and blood pressure, especially with excessive use.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report signs of liver injury (yellow skin/eyes, dark urine, abdominal pain) or blood dyscrasias (fever, sore throat, easy bruising) immediately.,Avoid alcohol completely while taking this medication.,May cause drowsiness or dizziness; avoid driving until you know how this drug affects you.,Use reliable contraception; phenacemide can harm a fetus and decrease effectiveness of hormonal contraceptives.,Do not stop abruptly; withdrawal can precipitate seizures.
Use AZMIRO exactly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking this medication without talking to your doctor.,Tell your doctor if symptoms worsen or you need more rescue inhaler.,Avoid foods high in potassium if you are also taking diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENURONE vs AZMIRO, answered by our medical review team.
PHENURONE is a Anticonvulsant that works by Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.. AZMIRO is a Anticonvulsant that works by Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENURONE and AZMIRO depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENURONE is: Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.. The standard adult dose of AZMIRO is: Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENURONE and AZMIRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENURONE is classified as Category C. Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.. AZMIRO is classified as Category C. No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.